Meanwhile, RIG-I agonist activates innate immunity and increases breast TILs in TME, and the combination of RIG-I agonist with anti-PD1 therapy significantly suppressed tumor development to a greater extent than either agent alone in vivo [116]. Here, RIGI is linked to neoplasm.